Background: L-arginine has been recently investigated and proposed to reduce neurological damage after various experimental models of neuronal cellular damage. In this study, we aim to evaluate the beneficial effects of L-arginine administration on the numerical density of dark neurons (DNs) in the substantia nigra pars compacta (SNc) of Balb/c mice subjected to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration.

Materials and Methods: Male Balb/c mice were randomly divided into 4 groups (n = 7 each): MPTP only; saline only (control); MPTP + L-arginine; and L-arginine only. The animals were infused intranasally with a single intranasal administration of the proneurotoxin MPTP (1 mg/nostril). L-arginine (300 mg/kg) was administrated intraperitoneally once daily for 1-week starting from 3 days after MPTP administration. Cavalieri principle method was used to estimate the numerical density of DNs in the SNc of different studied groups.

Results: Twenty days following MPTP administration, the number of DNs was significantly increased when compared to sham-control and L-arginine-control groups (P < 0.05). Nevertheless, our results showed that L-arginine administration significantly decreased the numerical density of DNs in SNc of mice.

Conclusion: This investigation provides new insights in experimental models of Parkinson's disease, indicating that L-arginine represents a potential treatment agent for dopaminergic neuron degeneration in SNc observed in Parkinson's disease patients.

Key Words: 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine, Balb/c mice, L-arginine, substantia nigra

INTRODUCTION

The substantia nigra (SN) - a crescent-shaped nucleus - lies in the midbrain immediately dorsal to the cerebral peduncles. This nucleus is an important motor center that is thought to be the lesion site in Parkinson’s disease (PD). PD is recognized as the second most common neurodegenerative disorder...
affecting 1% of the population worldwide after the age of 65 years. Movement impairments including tremor, bradykinesia, akinesia, rigidity, and postural instability are among the most obvious symptoms in the course of the disease. This disorder is caused by degeneration of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNc) that project to the striatum. The loss of DA neurons is responsible for the major symptoms of the disease. Although the most cases of PD are idiopathic, the etiology of DA neuronal demise is elusive. Dopamine degeneration process in PD involves oxidative stress, mitochondrial dysfunction, apoptotic processes, and microglial activation.  

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a systemic neurotoxin, which causes a specific loss of DA neurons in the nigrostriatal system, and recapitulates the permanent symptoms of PD. Therefore, in a series of earlier experimental investigations, intranasal (i.n.) administration of MPTP has become the most commonly used animal model of PD. In addition, the some of them demonstrated that low concentrations of MPTP can enter the brain via the olfactory mucosa and alter DA function in a range of brain structures. Because of safety considerations, the i.n. administration of MPTP which is not constrained by such factors may be more effective in getting higher levels of MPTP into the brain and to induce alterations in central nervous system structure and function.  

When MPTP is injected into an animal, the chemical penetrates the brain through the blood-brain barrier and is metabolized to 1-methyl-4-phenyl-2,3-dihydropyridine (MPP+) by monoamine oxidase-B enzyme in glia. MPP+ has a high affinity for the dopamine transporter (DAT) on DA cells and is taken up into the cell. MPP+ is then released from the glia and enters neurons via the DAT on DA cells. MPP+ is then accumulated in the mitochondria and creates further neuronal damage through the activation of reactive microglia and subsequent generation of free radicals. By 7-day postadministration of MPTP, a significant loss of DA neurons in the SNc is evident, along with a significant reduction of DA production in the terminal field within the striatum. Thus, MPTP administration to animals induces a DA neuron loss that mirrors the loss seen in end-stage PD.  

L-arginine is a semi-essential amino acid that involved in two major metabolic pathways. One of them is the nitric oxide synthase (NOS) pathway where L-arginine is converted to nitric oxide (NO) and L-citruline. The other pathway is the arginase pathway. L-arginine and its analogues are also potent NOS inhibitors. Growing evidence from studies in human PD brain, in addition to genetic and toxicological models, indicates that neurons of SN express the considerable amount of inducible nitric oxide synthase (iNOS). On the other hand, experimental and clinical findings show a close relationship between iNOS induction and neurodegeneration suggesting the inhibition of iNOS can have a therapeutic effect in PD. From etiological point, it is clearly showed that L-arginine have a regulatory effect on arterial pressure and improve blood flow after brain trauma resulting in neural death reduction.  

In previous experimental studies, dark neurons (DNs) production has been reported in the brain of animals exposed to various pathological conditions. DNs are the final product of a series of physico-chemical reactions initiated from extracellular milieu and propagate into the neuron. Morphologically DNs are characterized by at least six features namely: Hyperbasophilia, argyrophilia, disappearance of antigenicity, ultrastructural compaction, volume reduction, and increased electron density. This kind of degenerating neurons have been reported in Huntington disease, epilepsy, spreading depression, and also in aging process.  

Since L-arginine and its product, NO, exert such a range of critical roles in regulating physiological functions of the brain, we hypothesize that L-arginine can have a therapeutic effect on the MPTP-induced neurodegeneration in the SNc of mice. So, this study was designed to evaluate the beneficial effects of L-arginine on the numerical density of DNs in the SNc of Balb/c mice subjected intranasally to MPTP administration.  

**MATERIALS AND METHODS**  

**Animals and study design**  
Healthy adult male Balb/c mice (20–30 g body weight, 6–8-week-old) were purchased from the Experimental Animal Facility of Birjand University of Medical Sciences (Birjand, Iran). The animals were housed in polypropylene cages (four per cage) under controlled temperature and light conditions (22 ± 3°C, 40–70% relative humidity, 12-h light phase with daylight). They were fed with standard pellet diet (Javaneh co., Iran) and water *ad libitum*. All procedures involving animals were conducted in accordance with the guide for the care and use of Laboratory Animals of the Birjand University of Medical Sciences, Iran. All efforts were made to minimize animal suffering and to reduce the number of animals used. Mice were...
randomly assigned to four equal groups (n = 7 each):

- **Control Group:** Mice were administered intranasally with the same dose of vehicle (saline 0.9%)
- **MPTP Group:** Mice were administered intranasally with the single dose of MPTP (Sigma–Aldrich, St. Louis, MO, USA; dissolved in saline 0.9%) at the dose of 1 mg/nostril[14,43]
- **L-arginine Group:** Mice only received intraperitoneally L-arginine (Sigma–Aldrich, St. Louis, MO, USA; 300 mg/kg dissolved in saline 0.9%) once daily for 1-week
- **L-arginine - MPTP Group:** Mice received intraperitoneally L-arginine (Sigma–Aldrich, St. Louis, MO, USA; 300 mg/kg dissolved in saline 0.9%) once daily for 1-week starting from 3 days after MPTP administration.

MPTP (1 mg/nostril) was administered by i.n. route according to the procedure previously described[11,13,14] and modified in our laboratory. Briefly, mice were lightly anesthetized with xylazine/ketamine (10–75 mg/kg body weight, intraperitoneal injection) and a 7 mm piece of PE-10 tubing was inserted through the nostrils. The tubing was connected to a calibrated peristaltic pump set at a flow rate of 12.5 IU/min. The MPTP was dissolved in saline at a concentration of 20 mg/ml, after which it was infused at 1-min intervals for 4 min. The control solution consisted of saline. Animals were given a 1 min interval to regain normal respiratory function and then this procedure was repeated with infusions administered through the contralateral nostrils.

**Tissue preparation and toluidine blue staining**

Twenty days after the MPTP administration, mice were anesthetized with chloral hydrate (100 mg/kg). The mice were subjected to thoracotomy and perfusion with ice-cold 0.9% sodium chloride 50 ml and then with 4% paraformaldehyde 100 ml in 0.01 M phosphate buffered saline (PBS) through the left ventricle. After fixation, the brains were removed immediately and postfixed overnight at room temperature in the following fixative: 10% formaldehde in 0.01 M PBS.

Following fixation, samples were dehydrated using an ascending ethanol series, cleared in xylene, and infiltrated with paraffin. They were then embedded in paraffin and sectioned through the SN coronally at 5 μm thickness using rotary microtome (Leica, Germany). All of the sections containing substantia nigra[44] were mounted on slides. Sections were stained with 1% toluidine blue in 1% sodium borate for 1 min at 60°C.

**Quantification of dark degenerating neurons**

DNs in SNC were counted by an investigator blinded to the protocol treatment, using the optical disector technique described in detail by Gundersen et al.[45]. The optical disector technique eliminates bias in counting as a result of cell size and shape. Briefly, DNs were counted as they came into focus while scanning through the section.

For each section, 4–6 unbiased counting frames were sampled in a systematically random fashion inside the area of SNC. The preparations were examined under a light microscope using a × 60 objective lens (UPlanFI, Japan), and images were transferred to computer using a high-resolution camera (B × 51, Japan). The number of DNs was counted using a 10,000 μm² counting frame. The mean numbers of neurons per unit area in SNC were calculated using the formula as follows:

$$N_A = \frac{\Sigma \overline{Q}}{\mu} \frac{P}{f}$$

In this formula “∑Q̄” is the summation of counted DNs appeared in sections, “a/f” is the area associated with each frame (10,000 μm²), “∑P” is the sum of frames associated points hitting the reference space.

**Statistical analysis**

The numbers of 8–10 sections from each animal were averaged, and the data from seven animals of each group were presented as a mean ± standard error of the mean. Results were analyzed using one-way ANOVA, followed by Tukey’s post-hoc test for multiple comparisons between different groups studied. The level of statistical significance was set at P < 0.05. SPSS for Windows (Version 22; SPSS Inc., Chicago, IL, USA) was used to perform the total statistical analysis.

**RESULTS**

To explore the beneficial effects of L-arginine against MPTP-induced neuronal degeneration, toluidine blue staining was used to examine the numerical density of DNs in the SNC of Balb/c mice. Normal cells showed round and pale stained nuclei with a distinct nucleolus. The shrunken cells after MPTP administration with the morphological features of proapoptosis such as nuclear shrinkage and condensed chromatin were counted as DNs. To determine the numerical density of DNs in the SNC of Balb/c mice, we traced the boundaries for SNC as in Figure 1. The Numerical density of DNs was stereologically counted in SNC of mice in different studied groups.
Hami, et al.: The effect of L-arginine on parkinsonism rat

4

In control and L-arginine groups, there were a few numbers of DNs in SNc of the Balb/c mice [Figures 2 and 3a, c]. While following 20 days after MPTP administration induced severe DNs production. Our results revealed a marked increase in the number of DNs in SNc of the Balb/c mice in MPTP group when compared with both control and L-arginine groups ($P < 0.05$ and $P < 0.01$, respectively) [Figures 3a, b, d and Graph 1]. Additionally, the number of DNs in the L-arginine-MPTP group also increased significantly when compared with both control and L-arginine groups ($P < 0.05$ and $P < 0.01$, respectively) [Figures 2 and 3a, c, d].

Nevertheless, injection of L-arginine (300 mg/kg; i.p.) once daily for 7 days starting from 3 days after MPTP administration significantly decreased the numerical density of dark degenerating neurons in SNc subregion of substantia nigra of the Balb/c mice ($P < 0.05$); [Figure 3a, d, and Graph 1]. We found a statistical decrease in the number of DNs in the SNc in the L-arginine-MPTP group Balb/c mice comparing to the MPTP group ($P < 0.05$) [Figures 2 and 3a, d].

**DISCUSSION**

To our knowledge, this is the first report investigating the neuroprotective effects of L-arginine in the animal model of PD. The results of this study show a novel beneficial effect of L-arginine against MPTP-induced neurodegeneration in SN of Balb/c mice. The SN is an important motor center that is thought to be the lesion site in PD. Therefore, therapeutic or preventive strategies that stop or even slow the progress of PD are expected to have a major impact on the prevention or treatment of this kind of neurodegenerative disorders. A recent series of studies demonstrated that a single i.n. infusion of MPTP in rodents produces diverse signs of PD such as impairments in the motor, cognitive, and emotional functions. On the other hand, there is a little experience about the pharmacology of L-arginine administration in the doses given in experimental studies, especially in neurodegenerative diseases. Nevertheless, there is sufficient evidence suggesting that the 300-mg/kg dose of L-arginine in the rodents provides the best results. Recent studies on laboratory animals revealed that the administration of L-arginine has potential therapeutic importance, including anticonvulsant, anxiolytic, and antidepressant-like actions.

In this study, we showed that the repeated treatment with L-arginine during 7 consecutive days after MPTP administration was able to decrease significantly the numerical density of DNs in SNc of Balb/c mice administrated intranasally with MPTP. These data corroborate the therapeutic potential of L-arginine in PD, since it attenuated the DA cell loss in the SNc of Balb/c mice infused intranasally with MPTP.

**Figure 1:** Photomicrograph of coronal section from the substantia nigra in Balb/c mice substantia nigra pars compacta (red); substantia nigra pars reticulata (yellow) illustrating methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dark neurons production in substantia nigra pars compacta subregion where used for the stereological study. Regional boundaries were determined by cross-referencing with the atlases of Paxinos and Watson (2006)

**Figure 2:** $^*P < 0.05$; significant difference. $^*P < 0.01$; significant difference. Graph 1: Mean of dark neuron numbers per unit area (mm$^3$) in the substantia nigra pars compacta subdivision of Balb/c mice and its comparison in the different studied groups. The data show that the mean number of dark neurons per unit area in methyl-4-phenyl-1,2,3,6-tetrahydropyridine group significantly increased in substantia nigra pars compacta comparing to L-arginine and control Balb/c mice. Evaluation of therapeutic effects on dark neuron production in substantia nigra pars compacta subregion revealed a significant reduction in the mean number of dark neurons in L-arginine - methyl-4-phenyl-1,2,3,6-tetrahydropyridine group. Data present in mean ± standard error of the mean.
NOS,\textsuperscript{[51]} oxygen radical scavenging,\textsuperscript{[52]} blocking of N-methyl-D-aspartate (NMDA) receptors,\textsuperscript{[48-50]} and protection against mitochondrial membrane potential collapse.\textsuperscript{[53]} However, the sequence of events leading to the protective effects of L-arginine against cell damage has not been fully elucidated.\textsuperscript{[52,53]} In addition, the therapeutic effects of L-arginine administration could occur from its effects on the vasculature.\textsuperscript{[54]}

Some of beneficial effects L-arginine are also presumed to occur via production of NO, as L-arginine is the precursor of NO in the reaction mediated by the enzyme NOS. NO is produced by many different tissues and has numerous physiological and pathological effects.\textsuperscript{[21,55,56]} In the brain, NO plays a role as a neurotransmitter.\textsuperscript{[57]} Experimental studies have well documented the synthesis of NO in the brain, and its role in a variety of neuronal functions including learning and memory processes, cortical arousal, and blood vessel dilatation and immune response.\textsuperscript{[57]} NO is also a potent vasodilator and inhibits the platelet aggregation and leukocyte adhesion and may improve blood flow by preventing microvascular plugging by platelets and leukocytes.\textsuperscript{[58]}

The current hypothesis about the mechanisms by which neurons come into apoptotic or necrotic process of degeneration has led to belief that the use of drugs modulating the function of glutamate NMDA receptors may have beneficial effects in PD cases.\textsuperscript{[59]} There is increasing evidence of the beneficial effects of L-arginine blockades NMDA receptors, against different insults of the CNS.\textsuperscript{[48-50]} Previous studies have also demonstrated that MPTP decreases glutamate uptake by astrocytes in cell culture.\textsuperscript{[60]} Therefore, one possible mechanism by which L-arginine may exert beneficial effects against MPTP neurotoxicity may be due to the modulation of glutamate reuptake into neural cells.\textsuperscript{[60]}

In earlier investigations, administration of L-arginine has also been shown to increase cerebral blood flow and reduce neurological damage after experimental traumatic brain injury.\textsuperscript{[51,47,56,61]}

On the other hand, agmatine, formed by the decarboxylation of L-arginine, has been shown to be neuroprotective in experimental brain trauma and ischemia models.\textsuperscript{[43]} Recently, agmatine has been proposed as a novel neuromodulator that plays protective roles in several models of neuronal cellular damage.\textsuperscript{[43,62]} A study by Matheus et al.\textsuperscript{[43]} demonstrated that treatment with agmatine increased the survival rate of old mice infused with a single i.n. administration of MPTP, improving the general neurological status of the surviving animals. The researchers claimed that agmatine represents a novel potential therapeutic tool for the management of cognitive and motor symptoms of PD.\textsuperscript{[43]}

Of high importance, the administration of L-arginine demonstrated its protective properties as previously described in several models of neuronal damage.\textsuperscript{[61,63]} These results corroborate recent findings on L-arginine neuroprotection in cellular models of neurodegenerative diseases.\textsuperscript{[21]}

**CONCLUSIONS**

Taken together, these findings reinforce i.n. MPTP administration as a valuable rodent model for testing novel palliative compounds for PD. More importantly, this study provides the first preclinical data indicating that repeated systemic treatment with L-arginine prevents DA cell loss in the SNc of mice submitted to an experimental model of PD. These results provide new insights in experimental models of PD, indicating that L-arginine may represent a new neuroprotective agent from DA neuron degeneration observed in PD patients.

**Acknowledgments**

This work was financially supported by a Birjand University of Medical Sciences grant (no. 822). The authors gratefully thank Mr. Farid Rabiei and Mrs. Abolhasani students of Medical Sciences, Birjand University of Medical Sciences, Birjand, Iran, for their technical assistance.
Financial support and sponsorship
Birjand University of Medical Sciences grant (No. 822).

Conflicts of interest
There are no conflicts of interest.

REFERENCES
1. Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson’s disease. Mov Disord 2011;26:1049-55.
2. Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurol 2014;71:499-504.
3. Alves G, Forsaa EB, Pedersen KF, Dreytz Gjerstad M, Larsen JP. Epidemiology of Parkinson’s disease. J Neurol 2008;255 Suppl 5:18-32.
4. Shulman JM, De Jager PL, Feany MB. Parkinson’s disease: Genetics and pathogenesis. Annu Rev Pathol 2011;6:193-222.
5. Li LH, Qin HZ, Wang JL, Wang J, Wang XL, Gao GD. Axonal degeneration of nigra-striatum dopaminergic neurons induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J Int Med Res 2009;37:455-63.
6. Herrero MT, Luquín MR, Obeso JA. Experimental model of Parkinson disease: Mechanisms and anatomopathological characteristics of MPTP neurotoxicity. Arch Neurol (Madrid) 1992;55:175-82.
7. Kopin IJ. Features of the dopaminergic neurotoxin MPTP. Ann N Y Acad Sci 1992;648:96-104.
8. Lessel J. MPTP – Neurotoxin and model substance in Parkinson research. Pharm Unserer Zeit 1994;23:106-7.
9. Smeyne RJ, Jackson-Lewis V. The MPTP model of Parkinson’s disease. Brain Res Mol Brain Res 2005;134:57-66.
10. He XJ, Nakayama H, Dong M, Yamauchi H, Ueno M, Uetsuka K, et al. Evidence of apoptosis in the subventricular zone and rostral migratory stream in the MPTP mouse model of Parkinson disease. J Neuropathol Exp Neurol 2006;65:873-82.
11. Prediger RD, Aguiar AS Jr, Rojas-Mayorquin AE, Figueiredo CP, Mathes FC, Gineset L, et al. Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson’s disease. Neurotox Res 2010;17:114-29.
12. Roy A, Ghosh A, Jana A, Liu X, Brahmachari S, Gendelman HE, et al. Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson’s disease. PLoS One 2012;7:e38113.
13. Dziulon DE, Kefalas G. The effects of intranasal infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) upon catecholamine concentrations within olfactory bulbs and corpus striatum of male mice. Brain Res 1996;741:215-9.
14. Prediger RD, Aguiar AS Jr, Moreira EL, Mathes FC, Castro AA, Walz R, et al. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): A new rodent model to test palliative and neuroprotective agents for Parkinson’s disease. Curr Pharm Des 2011;17:489-507.
15. Prediger RD, Batista LC, Medeiros R, Pandolfo P, Florio JC, Takahashi RN. The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson’s disease. Exp Neurol 2006;202:391-403.
16. Prediger RD, Rial D, Medeiros R, Figueiredo CP, Doty RL, Takahashi RN. Risk is in the air: An intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson’s disease. Ann NY Acad Sci 2009;1170:829-36.
17. Ransoom BR, Kunis DM, Irwin I, Langston JW. Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+. Neurosci Lett 1987;75:323-8.
18. Cui M, Aras R, Christian WV, Rappold PM, Hatwar M, Panza J, et al. The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc Natl Acad Sci U S A 2009;106:8043-8.
19. Jenner P. Oxidative stress as a cause of Parkinson’s disease. Acta Neurol Scand Suppl 1991;136:6-15.
20. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 1995;4:257-69.
21. Virarkar M, Alappat L, Bradford PG, Awad AB. L-arginine and nitric oxide in CNS function and neurodegenerative diseases. Crit Rev Food Sci Nutr 2013;53:1567-77.
22. Yi J, Horky LL, Friedlich AL, Shi Y, Rogers JT, Huang X. L-arginine and Alzheimer’s disease. Int J Clin Exp Pathol 2009;2:211-38.
23. Rassat T, Kleinbongard P, Kelm M. The L-arginine nitric oxide pathway: Avenue for a multiple-level approach to assess vascular function. Biol Chem 2006;387:1347-9.
24. Kelm M. The L-arginine-nitric oxide pathway in hypertension. Curr Hypertens Rep 2003;5:80-6.
25. Otken NM, Osawa Y, Maretta MA. Characterization of the inactivation of nitric oxide synthase by NG-methyl-L-arginine: Evidence for heme loss. Biochemistry 1994;33:14784-91.
26. Barthwal MK, Srivastava N, Dikshit M. Role of nitric oxide in a progressive neurodegenerative model of Parkinson’s disease in the rat. Redox Rep 2001;6:297-302.
27. Santos RM, Lourenço CF, Leda A, Barbosa RM, Laranjinha J. Nitric oxide inactivation mechanisms in the brain: Role in bioenergetics and neurodegeneration. Int J Cell Biol 2012;2012:391914.
28. Contestabile A, Monti B, Contestabile A, Ciani E. Brain nitric oxide and its dual role in neurodegeneration/neuroprotection: Understanding molecular mechanisms to devise drug approaches. Curr Med Chem 2003;10:2147-74.
29. Molina JA, Jiménez-Jiménez FJ, Orti-Pareja M, Navarro JA. The role of nitric oxide in neurodegeneration. Potential for pharmacological intervention. Drugs Aging 1998;12:251-9.
30. Youdim MB, Lavi L, Riederer P. Oxygens free radicals and neurodegeneration in Parkinson’s disease: A role for nitric oxide. Ann NY Acad Sci 1994;738:64-8.
31. Lundblad C, Bentzer P. Effects of L-arginine on cerebral blood flow, microvascular permeability, number of perfused capillaries, and brain water content in the traumatized mouse brain. Microvasc Res 2007;74:1-8.
32. Willmot M, Gray L, Gibson C, Murphy S, Bath PM. A systematic review of nitric oxide donors and L-arginine in experimental stroke; effects on infant size and cerebral blood flow. Nitric Oxide 2005;12:141-9.
33. Kováč AG, Szabó C, Benyó Z, Csáki C, Greenberg JH, Reivich M. Effects of NG-nitro-L-arginine and L-arginine on regional cerebral blood flow in the rat. J Physiol 1992;449:183-96.
34. Ishida K, Shimizu H, Hida H, Urakawa S, Ida K, Nishino H. Argyrophilic dark neurons represent various states of neuronal damage in brain insults: Some come to die and others survive. Neuroscience 2004;125:633-44.
35. Gallays F, Kiglics V, Barackskay P, Juhász G, Czurkó A. The mode of death of epilepsy-induced “dark” neurons is neither necrosis nor apoptosis: An electron-microscopic study. Brain Res 2008;1239:207-15.
36. Kherani ZS, Auer RN. Pharmacologic analysis of the mechanism of dark neurons production in cerebral cortex. Acta Neuropathol 2008;116:447-52.
37. Ahmadpour SH, Haghir H. Diabetes mellitus type 1 induces dark neuron formation in the dentate gyrus: A study by Gallyas’ method and transmission electron microscopy. Rom J Morphol Embryol 2011;52:575-9.
38. Cammermeyer J I. An evaluation of the significance of the “dark” neuron. Ergeb Anat Entwicklungs gesch 1962;36:1-61.
39. Garman RH. The return of the dark neuron. A histological artifact complicating contemporary neurotoxicological evaluation. Neurotoxicology 2006;27:1126.
40. Jortner BS. The return of the dark neuron. A histological artifact complicating contemporary neurotoxicological evaluation. Neurotoxicology 2006;27:628-34.
41. Jafarian M, Rahimi S, Behnam F, Hosseini M, Haghir H, Sadeghzadeh B, et al. The effect of repetitive spreading depression on neuronal damage in juvenile rat brain. Neuroscience 2010;169:386-94.
42. Pucay K, Rasmussen H, Møller M, Preston T. Safety and toxicological
evaluation of a synthetic vitamin K2, menaquinone-7. Toxicol Mech Methods 2011;21:520-32.

43. Matheus FC, Aguiar AS Jr, Castro AA, Villarinho JG, Ferreira J, Figueiredo CP, et al. Neuroprotective effects of arginine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Behav Brain Res 2012;235:263-72.

44. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. 6th ed. New York: Elsevier; 2006.

45. Gundersen HJ, Bagger P, Bendtsen TF, Evans SM, Korbo L, Marcussen N, et al. The new stereological tools: Disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 1988;96:857-81.

46. Meissner W, Hill MP, Tison F, Gross CE, Bezard E. Neuroprotective strategies for Parkinson's disease: Conceptual limits of animal models and clinical trials. Trends Pharmacol Sci 2004;25:249-53.

47. Cherian L, Chacko G, Goodman C, Robertson CS. Neuroprotective effects of L-arginine administration after cortical impact injury in rats: Dose response and time window. J Pharmacol Exp Ther 2003;304:617-23.

48. Rosa AO, Lin J, Calixto JB, Santos AR, Rodrigues AL. Involvement of NMDA receptors and L-arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice. Behav Brain Res 2003;144:87-93.

49. Freitas AE, Moretti M, Budni J, Balen GO, Fernandes SC, Veronezi PO, et al. NMDA receptors and the L-arginine-nitric oxide-cyclic guanosine monophosphate pathway are implicated in the antidepressant-like action of the ethanolic extract from Tabebuia avellanedae in mice. J Med Food 2013;16:1030-8.

50. Ates-Alagoz Z, Adejare A. NMDA Receptor Antagonists for Treatment of Depression. Pharmaceuticals (Basel) 2013;6:480-99.

51. Jadeski LC, Lala PK. Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am J Pathol 1999;155:1381-90.

52. Tripathi P, Misra MK. Therapeutic role of L-arginine on free radical scavenging system in ischemic heart diseases. Indian J Biochem Biophys 2009;46:498-502.

53. Dedková EN, Blatter LA. Characteristics and function of cardiac mitochondrial nitric oxide synthase. J Physiol 2009;587:851-72.

54. Lerman A, Burnett JC Jr, Higano ST, McKinley LJ, Holmes DR Jr. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation 1998;97:2123-8.

55. Buchanan JE, Phillips JW. The role of nitric oxide in the regulation of cerebral blood flow. Brain Res 1993;610:248-55.

56. Garry PS, Ezra M, Rowland MJ, Westbrook J, Patterson KT. The role of the nitric oxide pathway in brain injury and its treatment – From bench to bedside. Exp Neurol 2015;263:235-43.

57. Garthwaite J, Boulton CL. Nitric oxide signaling in the central nervous system. Annu Rev Physiol 1995;57:683-706.

58. Iadecola C. Regulation of the cerebral microcirculation during neural activity: Is nitric oxide the missing link? Trends Neurosci 1993;16:206-14.

59. Bianconi F, Greenamyre JT, Nappi G. The role of glutamate in the pathophysiology of Parkinson’s disease. Funct Neurol 1996;11:3-15.

60. Hazell AS, Itzhak Y, Liu H, Norenberg MD. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) decreases glutamate uptake in cultured astrocytes. J Neurochem 1997;68:2216-9.

61. Cherian L, Chacko G, Goodman JC, Robertson CS. Cerebral hemodynamic effects of phenylephrine and L-arginine after cortical impact injury. Crit Care Med 1999;27:2512-7.

62. Condello S, Calabró E, Caccamo D, Curró M, Ferlazzo N, Satriano J, et al. Protective effects of arginine in rotenone-induced damage of human SH-SY5Y neuroblastoma cells: Fourier transform infrared spectroscopy analysis in a model of Parkinson’s disease. Amino Acids 2012;42:775-81.

63. Martínez-Orgado J, Fernández-Frutos B, González R, Fernández-López D, Uriüien L, Romero E, et al. Neuroprotective effect of L-arginine in a newborn rat model of acute severe asphyxia. Biol Neonate 2005;88:291-8.